This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Excellent news this a.m. ............ however!!!!! why do I get the feeling the mm's are holding this back????????

mitzy

You and GF are shrude operators, pro's i suspect. But I'm picking up negative vibes from your postings of today. Yours by saying "I would say be careful as a bad result from one of the trials could see this crashing down to 100p". And GF's qualifying reply's. You then went on to say "Killicks remain positive on the Genvax news due 18th Mar". But what about the Ruthenium results. Are these less positive, hence your cautiousness. Do you know something we don't but can't share. This is, to quote GF " One heck of a spectulative investment" so any info you've got would help us retailers from getting our fingers burned.
I don't mean to be picky but I do have a habit of reading between the lines and coming up with the wrong conclusion.

LOL

MS

YUP great news...............

Medical Marketing Int'l Group PLC
04 March 2005


For Immediate Release 4 March 2005



MMI's VIRATIS JOINT-VENTURE EXPANDS INTO AUTO-IMMUNE MARKET


Medical Marketing International Group plc (LSE:MMG), the Cambridge, UK-based
pharmaceutical development company announces that it has reached agreement with
its university partners, King's College London and Queen Mary, University of
London, to licence a novel technology aimed at treating auto-immune diseases
such as rheumatoid arthritis and asthma.


New technology aimed at treating diseases like rheumatoid arthritis and
asthma

Arthritis, inflammation and immune disorders biologicals market
predicted to grow by 20.1% per annum to $8.3bn by 2008

Patents for new technology already granted in USA, others pending


Dr David Brooks, Business Development Manager at MMI explained: 'Diseases such
as rheumatoid arthritis are believed to be caused by the patient's own immune
system over reacting and working against them. The new technology is akin to a
sponge, soaking up factors that activate genes implicated in asthma and
rheumatoid arthritis, so damping-down this over reaction and thereby treating
the cause of the disease.'


David Best, Chairman of MMI Group and of Viratis commenting on this new
agreement said: 'This latest agreement with King's and Queen Mary is yet another
endorsement of MMI's successful model of bringing commercial and development
skills to world class science from top universities. The addition of the new
technology to the HIV/AIDS and Hepatitis therapies already in Viratis provides
the company with a strong portfolio addressing key markets with unmet need. The
expanded portfolio of therapies in Viratis should further enhance shareholder
value in the longer term.'


For further information, please contact:


David Best - Executive Chairman
MMI Group

cheers GF.

From Killik Brokers morning notes...............

NEWS IN BRIEF



Medical Marketing, the pharmaceutical development company has announced a further tie up with Kings College and Queen Mary, University of London to licence a novel technology aimed at treating auto-immune diseases such as arthritis and asthma. The technology has already been granted a US patent. The deal serves to highlight MMI close relationship with the Universities, forged over many years, and its ability to identify interesting new technologies on a low budget. The stock price has been strong recently, more than doubling on a series of positive news flow. Investors are focusing on the imminent release of information relating to the Genvax trial which has been underway since 2001.

cheers GF.

Theres no problem mickey just a word of caution on how the market would react if the Genvax news was less than positive..if you remember back in September when the Genvax jv was first announced the sp actually went down on the news this was because over the last 30 years no one has quite managed to develop a Dna based platform technology that actually works.I too hope we will hear good news on the 18th of this month and that the sp hits 200p but like gf has said its a gamble until that time.
Regarding the Ruthenium news I expect to hear something after the Genvax news..and as far as know the clinical results have been much better than hoped for.
Killiks are positive and say all eyes are looking to the 18th.Compared to IPO2 the shares are still cheap imo.

mitzy

Thanks for that mitzy, I'll be able to sleep tonight, especially if I have too many Stella's in the Red Lion tonight. Is there such as thing as too many Stella's? Your the man.

LOL

MS

NO.

cheers GF

A bit of profit taking going on at the moment.

cheers GF.

No worries I'm anticipating a decent press coverage this weekend and about time you may say..the MMI story is impulsive and this is only the beginning..there is no doubt the sp will be 200p in 2 weeks time.

If it going to be 2 quid in two weeks time Mitzy, shouldny you be upping your year end figure?, I totaly support you but I think your being a bit miserly saying it will only hit 3 quid by the year end, Im sure you said this, but could be wrong and would love to be proved wrong.

cheers GF.

Yes I reckon a figure of 350p in a year from now but the 200p will be due around the time of the Genvax update... so the trading range is between 200p andv350p going forward..cheers.

Thanks for the update Mitzy , I think your being rather conservative, but Ill take those figure anyday.

cheers GF.

Up this morning on decent volume but looks like the mms by a cobination of a large spread and failure to rise the price as in the past are holding this one back for the 18th.

cheers GF.

All very quiet on this one today I expect everyone is waiting for the update on the 18th inst..

Yes Mitzy that amount of buy volume today would have probably moved this one up 10p a fortnight ago.

cheers GF.

"there is no doubt the sp will be 200p in 2 weeks time" (mitzy).

If there was no doubt, it would be there already.
If Genvax passes Phase 2 you still only have a 30% chance that the drug will get to market.
MMG own only 50% of Genvax so if their target market is worth say $1bn (annual sales) and Genvax manages to get 10% (speculation) of that market, that puts MMG's % of sales at $50m but they will only get royalties as they will not manufacture or distribute. Say royalties at 25% of $50m = $12.5m annually.
Assuming we reach Phase III, we still only have a 30% chance of success.
This puts a current value on Genvax Follicular NHL vaccine in Phase III at $4.125M.
I have used approximate industry averages which vary from paper to paper so must be used as approximation.
Please feel free to question my calcs.

So how much is 4million PER ANNUM worth- say 40 million? Fair?

Good point. I think thats the usual valuation method (x 10).

My biggest variable is how big is the North American and European market in $.
Roche have a Follicular NHL drug (mabThera) which is quite new so no revenue figures but I think they hope to achieve $1bn sales annually.
If Genvax is that successful (1bn sales annually )and all the other figures remain, that puts current value at $41.25M rising to $125M if we reach market.
Fair value at 412.5M in P3 or 1.25Bn in market.

Pete 168 some valuable imput here from you and S101.

I assumed myself and I think others did that Mitzy was talking when he said 200p in two weeks that he was very confident that the drug would pass the Phase 2 trial. He as said elsewhere Like I have that its the flip of a coin a 50/50 chance, it will either pass or fail. If it passes and he seems very confident and I would say his track record so far on this investment as been 100% I feel he could be right on his assesment of the share price, we will see come the 18th.

cheers GF.

There are levels of success.
Is it as good as current best drug?
Is it 10% better than current best drug?
Is it 50% better than current best drug?

Alot of variables to take in which will have a huge influence over valuation of Genvax.
Of course if it is alot better than current best drug, as it is a platform technology, you have the other two vaccines which are in trials for prostate and colon cancer followed by others.
Lets hope for good news on the 18th.